Search hospitals > Alberta > CALGARY
Alberta Children's Hospital
Claim this profileCALGARY, Alberta T3B 6A8
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Acute Lymphoblastic Leukemia
Conducts research for Uterine Tumors
Conducts research for Leukemia
Conducts research for Brain Tumor
308 reported clinical trials
20 medical researchers
Summary
Alberta Children's Hospital is a medical facility located in CALGARY, Alberta. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Acute Lymphoblastic Leukemia, Uterine Tumors, Leukemia, Brain Tumor and other specialties. Alberta Children's Hospital is involved with conducting 308 clinical trials across 539 conditions. There are 20 research doctors associated with this hospital, such as Victor Lewis, MD, Aneal Khan, Lucie Lafay-Cousin, MD, and Jean Mah, MD.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
Stage IV
Stage III
2Acute Lymphoblastic Leukemia
Global LeaderStage II
Stage IV
Stage III
Top PIs
Victor Lewis, MDAlberta Children's Hospital5 years of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies T-Lymphoblastic Leukemia/Lymphoma
28 reported clinical trials
81 drugs studied
Aneal KhanMAGIC Clinic Ltd6 years of reported clinical research
Studies Fabry Disease
Studies Postprandial Fullness Syndrome
9 reported clinical trials
10 drugs studied
Lucie Lafay-Cousin, MDAlberta Children's Hospital6 years of reported clinical research
Studies Cerebral Gliomas
Studies Brain Tumor
6 reported clinical trials
10 drugs studied
Jean Mah, MDAlberta's Children Hospital8 years of reported clinical research
Studies Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
3 reported clinical trials
4 drugs studied
Clinical Trials running at Alberta Children's Hospital
Testicular cancer
Acute Lymphoblastic Leukemia
Obesity
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Brain Tumor
Sickle Cell Disease
Germ Cell Tumors
Uterine Tumors
Ovarian Tumors
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Alberta Children's Hospital?
Alberta Children's Hospital is a medical facility located in CALGARY, Alberta. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Acute Lymphoblastic Leukemia, Uterine Tumors, Leukemia, Brain Tumor and other specialties. Alberta Children's Hospital is involved with conducting 308 clinical trials across 539 conditions. There are 20 research doctors associated with this hospital, such as Victor Lewis, MD, Aneal Khan, Lucie Lafay-Cousin, MD, and Jean Mah, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.